MA28110A1 - Antagonistes du recepteur d'acetylcholine muscarinique - Google Patents

Antagonistes du recepteur d'acetylcholine muscarinique

Info

Publication number
MA28110A1
MA28110A1 MA28964A MA28964A MA28110A1 MA 28110 A1 MA28110 A1 MA 28110A1 MA 28964 A MA28964 A MA 28964A MA 28964 A MA28964 A MA 28964A MA 28110 A1 MA28110 A1 MA 28110A1
Authority
MA
Morocco
Prior art keywords
antagonists
muscarinic receptor
acetylcholine muscarinic
acetylcholine
receptor antagonists
Prior art date
Application number
MA28964A
Other languages
English (en)
Inventor
Jakob Busch-Petersen
Michael R Palovich
Zehong Wan
Hongxing Yan
Chongjie Zhu
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28110A1 publication Critical patent/MA28110A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Abstract

Antagonistes du récepteur d'acétylcholine muscarinique Des antagonistes des récepteurs d'acétylcholine muscariniques et des méthodes pour leur utilisation sont proposés.
MA28964A 2003-10-14 2006-04-25 Antagonistes du recepteur d'acetylcholine muscarinique MA28110A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51100903P 2003-10-14 2003-10-14

Publications (1)

Publication Number Publication Date
MA28110A1 true MA28110A1 (fr) 2006-08-01

Family

ID=34465175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28964A MA28110A1 (fr) 2003-10-14 2006-04-25 Antagonistes du recepteur d'acetylcholine muscarinique

Country Status (34)

Country Link
US (3) US7276521B2 (fr)
EP (1) EP1677795B1 (fr)
JP (4) JP2007508390A (fr)
KR (3) KR20060106821A (fr)
CN (3) CN101230062A (fr)
AP (3) AP1828A (fr)
AR (1) AR046103A1 (fr)
AT (1) ATE494285T1 (fr)
AU (1) AU2004281724B2 (fr)
BR (1) BRPI0415361A (fr)
CA (1) CA2542657C (fr)
CY (1) CY1111364T1 (fr)
DE (1) DE602004030930D1 (fr)
DK (1) DK1677795T3 (fr)
EA (3) EA013689B1 (fr)
EC (1) ECSP066468A (fr)
ES (1) ES2358673T3 (fr)
HR (1) HRP20110232T1 (fr)
IL (2) IL174843A0 (fr)
IS (1) IS2918B (fr)
MA (1) MA28110A1 (fr)
MX (1) MXPA06004244A (fr)
MY (1) MY143366A (fr)
NO (1) NO20062042L (fr)
NZ (2) NZ556424A (fr)
OA (1) OA13316A (fr)
PE (1) PE20050963A1 (fr)
PL (1) PL1677795T3 (fr)
PT (1) PT1677795E (fr)
SG (1) SG147436A1 (fr)
SI (1) SI1677795T1 (fr)
TW (3) TWI409060B (fr)
UA (2) UA89734C2 (fr)
WO (1) WO2005037280A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
TWI409060B (zh) 2003-10-14 2013-09-21 Glaxo Group Ltd 蕈毒鹼乙醯膽鹼受器拮抗劑
BRPI0415281A (pt) * 2003-10-17 2006-12-19 Glaxo Group Ltd antagonistas de receptor de acetilcolina muscarìnico
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1725236A4 (fr) * 2004-03-11 2009-05-13 Glaxo Group Ltd Nouveaux antagonistes du recepteur de l'acetylcholine muscarinique m3
EP1725564A4 (fr) * 2004-03-17 2007-09-12 Glaxo Group Ltd Antagonistes du recepteur d'acetylcholine muscarinique m3
WO2005094251A2 (fr) * 2004-03-17 2005-10-13 Glaxo Group Limited Antagonistes du recepteur muscarinique a l'acetylcholine m3
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
US7598267B2 (en) * 2004-05-13 2009-10-06 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US7932247B2 (en) * 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007016639A2 (fr) * 2005-08-02 2007-02-08 Glaxo Group Limited Antagonistes des recepteurs de l' acetylcholine muscarinique m3
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
TW200811111A (en) 2006-04-20 2008-03-01 Glaxo Group Ltd Novel compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
WO2008015416A1 (fr) 2006-08-01 2008-02-07 Glaxo Group Limited Composés de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de pde4
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
JP2010539182A (ja) * 2007-09-12 2010-12-16 グラクソ グループ リミテッド 治療剤の新規組み合わせ
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
TW200946525A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
TW200946526A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
WO2009147187A1 (fr) 2008-06-05 2009-12-10 Glaxo Group Limited Dérivés de 4-carboxamide indazole utiles en tant qu'inhibiteurs de p13 kinases
ATE552255T1 (de) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
WO2010094643A1 (fr) 2009-02-17 2010-08-26 Glaxo Group Limited Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
WO2010097114A1 (fr) * 2009-02-26 2010-09-02 Glaxo Group Limited Nouvelle combinaison d'agents thérapeutiques
PL2400950T3 (pl) 2009-02-26 2019-12-31 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
EP2406249A1 (fr) 2009-03-10 2012-01-18 Glaxo Group Limited Dérivés d'indole comme inhibiteurs de ikk2
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors
DK2899191T3 (da) 2009-04-30 2017-11-13 Glaxo Group Ltd Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011067365A1 (fr) 2009-12-03 2011-06-09 Glaxo Group Limited Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
EP2507231A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Dérivés d'indazole comme inhibiteurs des pi3-kinases
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
SI2614058T1 (sl) 2010-09-08 2015-10-30 Glaxosmithkline Intellectual Property Development Limited Polimorfi in soli N-(5-(4-(5-(((2R,6S)-2,6-dimetil-4-morfolinil)metil)-1,3-oksazol-2-il)- 1H-indazol-6-il)-2-(metiloksi)-3-piridinil)metansulfonamida
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
WO2013153146A1 (fr) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Particules agrégées
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
CA2923995A1 (fr) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
US20160263109A1 (en) 2013-10-17 2016-09-15 Glaxosmithkline Intellectual Property Development Limited P13k inhibitor for treatment of respiratory disease
SG11201609276RA (en) 2014-05-12 2016-12-29 Glaxosmithkline Ip No 2 Ltd Pharmaceutical compositions comprising danirixin for treating infectious diseases
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
JP2023519585A (ja) 2020-03-26 2023-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ウイルス感染を予防または治療するカテプシン阻害剤

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800482A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Olefinic derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
CA1224992A (fr) 1982-10-08 1987-08-04 Robert E. Newell Dispositif pour l'administration d'un medicament a un patient
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9000304D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Muscarinic receptor antagonists
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
JP3294961B2 (ja) * 1993-12-10 2002-06-24 杏林製薬株式会社 新規イミダゾール誘導体及びその製造法
JPH08291141A (ja) * 1995-04-21 1996-11-05 Kotobuki Seiyaku Kk ジフェニル酢酸誘導体及びその製造法
JPH0920758A (ja) * 1995-07-06 1997-01-21 Kyorin Pharmaceut Co Ltd 新規環状ジアミン誘導体及びその製造法
AU5790598A (en) * 1996-12-02 1998-06-29 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IL160896A0 (en) * 2001-10-17 2004-08-31 Ucb Sa Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
DE10211700A1 (de) * 2002-03-16 2003-09-25 Boehringer Ingelheim Pharma Neue Difurylglykolsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
US7232841B2 (en) * 2003-04-07 2007-06-19 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
TW200519109A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR045913A1 (es) 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
TWI409060B (zh) * 2003-10-14 2013-09-21 Glaxo Group Ltd 蕈毒鹼乙醯膽鹼受器拮抗劑
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1685118B1 (fr) * 2003-11-21 2009-07-08 Theravance, Inc. Composes ayant une activite agoniste de recepteur adrenergique beta 2 et antagoniste de recepteur muscarinique
WO2006050239A2 (fr) 2004-10-29 2006-05-11 Glaxo Group Limited Antagonistes des recepteurs de l'acetylcholine muscarinique
JP2008520573A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US7932247B2 (en) 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (fr) 2004-12-13 2006-06-22 Glaxo Group Limited Nouveaux antagonistes du recepteur muscarinique de l'acetylcholine
WO2006065755A2 (fr) 2004-12-13 2006-06-22 Glaxo Group Limited Sels d'ammonium quaternaire d'amines heteroaromatiques fusionnees utilises comme nouveaux antagonistes du recepteur de l'acetylcholine muscarinique
WO2007018508A1 (fr) 2005-07-28 2007-02-15 Glaxo Group Limited Nouveaux antagonistes du récepteur muscarinique m3 de l’acétylcholine
WO2007018514A1 (fr) 2005-07-28 2007-02-15 Glaxo Group Limited Nouveaux antagonistes récepteurs d’acétylcholine muscarinique m3
WO2007016650A2 (fr) 2005-08-02 2007-02-08 Glaxo Group Limited Antagonistes du recepteur d'acetylcholine muscarinique m3
WO2007016639A2 (fr) 2005-08-02 2007-02-08 Glaxo Group Limited Antagonistes des recepteurs de l' acetylcholine muscarinique m3
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system

Also Published As

Publication number Publication date
EP1677795A1 (fr) 2006-07-12
KR20080067023A (ko) 2008-07-17
KR20060106821A (ko) 2006-10-12
CN101230062A (zh) 2008-07-30
US20070238752A1 (en) 2007-10-11
EA200600773A1 (ru) 2008-04-28
EA200702619A1 (ru) 2008-04-28
EA013435B1 (ru) 2010-04-30
IL188112A (en) 2012-10-31
EP1677795B1 (fr) 2011-01-05
AU2004281724B2 (en) 2010-07-15
KR20080065318A (ko) 2008-07-11
MXPA06004244A (es) 2006-06-28
TWI409060B (zh) 2013-09-21
TW200811171A (en) 2008-03-01
AP2006003566A0 (en) 2006-04-30
CN101230061A (zh) 2008-07-30
IS8441A (is) 2006-05-05
US7576096B2 (en) 2009-08-18
CA2542657A1 (fr) 2005-04-28
UA89734C2 (en) 2010-02-25
CA2542657C (fr) 2011-03-01
TW200811172A (en) 2008-03-01
UA87473C2 (en) 2009-07-27
WO2005037280A1 (fr) 2005-04-28
AP2007004238A0 (en) 2007-12-31
ES2358673T3 (es) 2011-05-12
US7579361B2 (en) 2009-08-25
JP4796552B2 (ja) 2011-10-19
NZ546312A (en) 2008-09-26
MY143366A (en) 2011-04-29
SG147436A1 (en) 2008-11-28
OA13316A (en) 2007-04-13
JP2011162556A (ja) 2011-08-25
SI1677795T1 (sl) 2011-04-29
NO20062042L (no) 2006-05-08
TW200522933A (en) 2005-07-16
JP5450509B2 (ja) 2014-03-26
PT1677795E (pt) 2011-04-01
US7276521B2 (en) 2007-10-02
ECSP066468A (es) 2006-11-16
PL1677795T3 (pl) 2011-05-31
AP1828A (en) 2008-02-13
EA009899B1 (ru) 2008-04-28
JP2007314567A (ja) 2007-12-06
EP1677795A4 (fr) 2006-12-27
US20070244150A1 (en) 2007-10-18
BRPI0415361A (pt) 2006-12-12
HRP20110232T1 (hr) 2011-05-31
ATE494285T1 (de) 2011-01-15
AP2007004239A0 (en) 2007-12-31
AR046103A1 (es) 2005-11-23
NZ556424A (en) 2008-12-24
EA013689B1 (ru) 2010-06-30
CN1893948A (zh) 2007-01-10
IL188112A0 (en) 2008-03-20
PE20050963A1 (es) 2006-01-11
DE602004030930D1 (de) 2011-02-17
JP2007508390A (ja) 2007-04-05
JP2007277276A (ja) 2007-10-25
CY1111364T1 (el) 2015-08-05
AU2004281724A1 (en) 2005-04-28
DK1677795T3 (da) 2011-04-18
US20070105895A1 (en) 2007-05-10
IS2918B (is) 2015-01-15
EA200702617A1 (ru) 2008-04-28
IL174843A0 (en) 2006-08-20

Similar Documents

Publication Publication Date Title
MA28110A1 (fr) Antagonistes du recepteur d&#39;acetylcholine muscarinique
MA27900A1 (fr) Antagonistes du recepteur de l&#39;acetylcholine muscarinique
MA27901A1 (fr) Antagonistes du recepteur de l&#39;acetylcholine muscarinique
MA28109A1 (fr) Antagonistes du recepteur acetylcholine muscarinique
MA27973A1 (fr) Antagonistes du recepteur de l&#39;acetylcholine muscarinique
MA28218A1 (fr) Nouveaux antagonistes de recepteur d&#39;acetylcholine muscarinique m3
MA28217A1 (fr) Nouveaux antagonistes de recepteur d&#39;acetylcholine muscarinique m3
CY1118082T1 (el) Ανταγωνιστες μουσκαρινικου υποδοχεα ακετυλοχολινης
CY1113295T1 (el) Ανταγωνιστες m3 μουσκαρινικου υποδοχεα ακετυλοχολινης
TW200600093A (en) M3 muscarinic acetylcholine receptor antagonists
TW200600500A (en) M3 muscarinic acetylcholine receptor antagonists
TW200633715A (en) Medical combinations
MA28363A1 (fr) Antagonistes des recepteurs muscariniques de l&#39;acetylcholine
MA29080B1 (fr) Derives de la quinuclidine et leur utilisation en tant qu&#39;antagonistes du recepteur m3 muscarinique
DE602005026169D1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
FR2857993B3 (fr) Dispositif pour l&#39;hygiene des urinoirs